Phar­ma reps need to bone up on sci­en­tif­ic da­ta and re­al-world ev­i­dence for on­col­o­gy dis­cus­sions: study

On­col­o­gists would like a word with phar­ma com­pa­nies. More than a word, ac­tu­al­ly – they’d like en­tire in-depth con­ver­sa­tions with drug ex­perts and more re­al-world da­ta, please.

That’s ac­cord­ing to Ac­cen­ture’s new study look­ing at on­col­o­gists’ needs through a phar­ma lens. The study comes as FDA ap­proved 16 nov­el can­cer drugs in 2021 – in­clud­ing the first KRAS in­hibitor – along with more than 40 new in­di­ca­tions in on­col­o­gy and hema­tol­ogy. Mean­while, on­col­o­gy tri­als are at record lev­els, up 60% from just five years ago, Ac­cen­ture not­ed in its re­port.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.